4//SEC Filing
Chione Ltd 4
Accession 0001213900-22-074313
CIK 0001781174other
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 6:26 PM ET
Size
21.9 KB
Accession
0001213900-22-074313
Insider Transaction Report
Form 4
Czernik Marcin
10% Owner
Transactions
- Conversion
Common Stock
2022-11-17+3,445,940→ 3,856,597 total - Conversion
Common Stock
2022-11-17+10,657→ 3,856,597 total - Conversion
Series A-1 Preferred Stock
2022-11-17−8,497,692→ 0 total→ Common Stock (3,445,940 underlying) - Purchase
Common Stock
2022-11-17$12.50/sh+400,000$5,000,000→ 3,856,597 total - Conversion
Series B Preferred Stock
2022-11-17−26,281→ 0 total→ Common Stock (10,657 underlying)
Hadjimichael Andreas
10% Owner
Transactions
- Conversion
Common Stock
2022-11-17+10,657→ 3,856,597 total - Conversion
Series B Preferred Stock
2022-11-17−26,281→ 0 total→ Common Stock (10,657 underlying) - Purchase
Common Stock
2022-11-17$12.50/sh+400,000$5,000,000→ 3,856,597 total - Conversion
Common Stock
2022-11-17+3,445,940→ 3,856,597 total - Conversion
Series A-1 Preferred Stock
2022-11-17−8,497,692→ 0 total→ Common Stock (3,445,940 underlying)
Nikolaou Anastasis
10% Owner
Transactions
- Conversion
Common Stock
2022-11-17+10,657→ 3,856,597 total - Conversion
Series B Preferred Stock
2022-11-17−26,281→ 0 total→ Common Stock (10,657 underlying) - Conversion
Common Stock
2022-11-17+3,445,940→ 3,856,597 total - Conversion
Series A-1 Preferred Stock
2022-11-17−8,497,692→ 0 total→ Common Stock (3,445,940 underlying) - Purchase
Common Stock
2022-11-17$12.50/sh+400,000$5,000,000→ 3,856,597 total
Chione Ltd
10% Owner
Transactions
- Conversion
Series A-1 Preferred Stock
2022-11-17−8,497,692→ 0 total→ Common Stock (3,445,940 underlying) - Conversion
Common Stock
2022-11-17+10,657→ 3,856,597 total - Purchase
Common Stock
2022-11-17$12.50/sh+400,000$5,000,000→ 3,856,597 total - Conversion
Series B Preferred Stock
2022-11-17−26,281→ 0 total→ Common Stock (10,657 underlying) - Conversion
Common Stock
2022-11-17+3,445,940→ 3,856,597 total
Smolokowski Wiaczeslaw
10% Owner
Transactions
- Purchase
Common Stock
2022-11-17$12.50/sh+400,000$5,000,000→ 3,856,597 total - Conversion
Common Stock
2022-11-17+3,445,940→ 3,856,597 total - Conversion
Common Stock
2022-11-17+10,657→ 3,856,597 total - Conversion
Series B Preferred Stock
2022-11-17−26,281→ 0 total→ Common Stock (10,657 underlying) - Conversion
Series A-1 Preferred Stock
2022-11-17−8,497,692→ 0 total→ Common Stock (3,445,940 underlying)
Footnotes (5)
- [F1]Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date.
- [F2]Shares owned directly by Chione Limited ("Chione").
- [F3]Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione.
- [F4]Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
- [F5]Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.
Documents
Issuer
Acrivon Therapeutics, Inc.
CIK 0001781174
Entity typeother
IncorporatedCyprus
Related Parties
1- filerCIK 0001590232
Filing Metadata
- Form type
- 4
- Filed
- Nov 20, 7:00 PM ET
- Accepted
- Nov 21, 6:26 PM ET
- Size
- 21.9 KB